Dec 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's MSB.AX cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.
(Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.